<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg"/></p>
<p>CIB-301 通过完全人源化的 CAR scFv 靶向实体肿瘤。图片来源：Vshivkova / Shutterstock.com。</p>
<p></p>
<p>uBriGene Biosciences 与 Cellinfinity BIO 签署了战略合作伙伴关系，以推进针对血液和实体肿瘤的体内嵌合抗原受体 T 细胞（CAR-T）疗法的临床开发。</p>
<p>该合作伙伴关系专注于推进 Cellinfinity BIO 的 CIB-301 和 CIB-350 项目。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多发性骨髓瘤中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Alaunos Therapeutics Inc 的肿瘤基因疗法 2</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>uBriGene 的 LVV Turbo 平台将提供良好生产规范（GMP）下的慢病毒载体制造、生产、工艺开发和监管支持。</p>
<p>该平台整合了三项技术：完全封闭的下游纯化过程、超增强剂和高产率的 293TH 悬浮细胞系。</p>
<p>在纯化过程中可实现高达 80% 的回收率，并将 T 细胞转导滴度提高五倍。</p>
<p>CIB-301 通过设计为低脱靶风险的完全人源化 CAR 单链可变片段（scFv）靶向实体肿瘤。</p>
<p>它针对与结直肠癌、子宫内膜癌、非小细胞肺癌、卵巢癌和肾细胞癌相关的肿瘤抗原。</p>
<p>CIB-350 采用双特异性 CAR 设计，靶向自身免疫疾病和血液恶性肿瘤，能够同时靶向两个 B 细胞抗原。</p>
<p>uBriGene 提供集成的合同开发和制造组织（CDMO）及合同研究组织（CRO）服务，专注于细胞疗法、病毒载体和核糖核酸（RNA）相关产品。</p>
<p>其全球 GMP 卓越中心支持客户开发下一代疗法。</p>
<p>Cellinfinity BIO 的平台专注于对实体肿瘤进行精确的 T 细胞调节，旨在增强持久性和安全性，同时在临床前模型中展示抗肿瘤活性。</p>
<p>uBriGene 联合创始人兼首席技术官 Dr. Sun Xiulian 表示：“我们对与 Cellinfinity Bio 的战略合作伙伴关系感到兴奋。体内 CAR-T 技术有潜力显著降低治疗成本。</p>
<p>“利用我们高产的 LVV Turbo 慢病毒载体平台和 GMP 制造专业知识，我们旨在降低 CAR-T 疗法的商品成本，提高患者的可及性和负担能力。”</p>
<p><em>Pharmaceutical Technology 上的细胞与基因疗法报道由 Cytiva 支持。</em></p>
<p><em>编辑内容独立制作，遵循</em> 最高标准 <em>的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>

2 倍做多纳斯达克生物技术 ETF - ProShares

华夏恒生生物科技ETF(QDII)

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>uBriGene Biosciences 已与 Cellinfinity BIO 达成合作，推进针对血液和实体肿瘤的体内 CAR-T 疗法。此次合作重点关注 CIB-301 和 CIB-350 项目，利用 uBriGene 的 LVV Turbo 平台进行 GMP 慢病毒载体的生产。CIB-301 针对具有完全人源 CAR scFv 的实体肿瘤，而 CIB-350 则针对自身免疫疾病和血液恶性肿瘤。该合作旨在降低治疗成本，提高患者对 CAR-T 疗法的可及性</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg"/></p>
<p>CIB-301 targets solid tumours using a fully human CAR scFv. Credit: Vshivkova / Shutterstock.com.</p>
<div class="lb-trans"><p>CIB-301 通过完全人源化的 CAR scFv 靶向实体肿瘤。图片来源：Vshivkova / Shutterstock.com。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen receptor T-cell (CAR-T) therapy programmes for haematologic and solid tumours.</p>
<div class="lb-trans"><p>uBriGene Biosciences 与 Cellinfinity BIO 签署了战略合作伙伴关系，以推进针对血液和实体肿瘤的体内嵌合抗原受体 T 细胞（CAR-T）疗法的临床开发。</p>
</div><p>The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350.</p>
<div class="lb-trans"><p>该合作伙伴关系专注于推进 Cellinfinity BIO 的 CIB-301 和 CIB-350 项目。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多发性骨髓瘤中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Alaunos Therapeutics Inc's Gene Therapy 2 for Oncology</h4>
<div class="lb-trans"><h4>NPVM: Alaunos Therapeutics Inc 的肿瘤基因疗法 2</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and regulatory support for these therapies.</p>
<div class="lb-trans"><p>uBriGene 的 LVV Turbo 平台将提供良好生产规范（GMP）下的慢病毒载体制造、生产、工艺开发和监管支持。</p>
</div><p>The platform integrates three technologies: a fully closed downstream purification process, the ultra-T enhancer, and a high-productivity 293TH suspension cell line.</p>
<div class="lb-trans"><p>该平台整合了三项技术：完全封闭的下游纯化过程、超增强剂和高产率的 293TH 悬浮细胞系。</p>
</div><p>It achieves up to 80% recovery during purification and boosts T-cell transduction titres by five times.</p>
<div class="lb-trans"><p>在纯化过程中可实现高达 80% 的回收率，并将 T 细胞转导滴度提高五倍。</p>
</div><p>CIB-301 targets solid tumours with a fully human CAR single-chain variable fragment (scFv) designed for low off-target risk.</p>
<div class="lb-trans"><p>CIB-301 通过设计为低脱靶风险的完全人源化 CAR 单链可变片段（scFv）靶向实体肿瘤。</p>
</div><p>It addresses tumour antigens related to colorectal cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.</p>
<div class="lb-trans"><p>它针对与结直肠癌、子宫内膜癌、非小细胞肺癌、卵巢癌和肾细胞癌相关的肿瘤抗原。</p>
</div><p>CIB-350 targets autoimmune diseases and haematologic malignancies with a bispecific CAR design able to target two B-cell antigens simultaneously.</p>
<div class="lb-trans"><p>CIB-350 采用双特异性 CAR 设计，靶向自身免疫疾病和血液恶性肿瘤，能够同时靶向两个 B 细胞抗原。</p>
</div><p>uBriGene offers integrated contract development and manufacturing organisation (CDMO) and contract research organisation (CRO) services for cell therapies, viral vectors, and ribonucleic acid (RNA)-related products.</p>
<div class="lb-trans"><p>uBriGene 提供集成的合同开发和制造组织（CDMO）及合同研究组织（CRO）服务，专注于细胞疗法、病毒载体和核糖核酸（RNA）相关产品。</p>
</div><p>Its global GMP Centers of Excellence support clients in developing next-generation therapies.</p>
<div class="lb-trans"><p>其全球 GMP 卓越中心支持客户开发下一代疗法。</p>
</div><p>Cellinfinity BIO’s platforms focus on precise T-cell modulation for solid tumours, aiming to enhance persistence and safety while demonstrating anti-tumour activity in preclinical models.</p>
<div class="lb-trans"><p>Cellinfinity BIO 的平台专注于对实体肿瘤进行精确的 T 细胞调节，旨在增强持久性和安全性，同时在临床前模型中展示抗肿瘤活性。</p>
</div><p>uBriGene co-founder and CTO Dr Sun Xiulian said: “We are excited about this strategic partnership with Cellinfinity Bio. In vivo CAR-T technologies have the potential to significantly reduce treatment costs.</p>
<div class="lb-trans"><p>uBriGene 联合创始人兼首席技术官 Dr. Sun Xiulian 表示：“我们对与 Cellinfinity Bio 的战略合作伙伴关系感到兴奋。体内 CAR-T 技术有潜力显著降低治疗成本。</p>
</div><p>“Leveraging our highly productive LVV Turbo lentiviral vector platform and GMP manufacturing expertise, we aim to lower the cost of goods for CAR-T therapies, improving patient accessibility and affordability.”</p>
<div class="lb-trans"><p>“利用我们高产的 LVV Turbo 慢病毒载体平台和 GMP 制造专业知识，我们旨在降低 CAR-T 疗法的商品成本，提高患者的可及性和负担能力。”</p>
</div><p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>
<div class="lb-trans"><p><em>Pharmaceutical Technology 上的细胞与基因疗法报道由 Cytiva 支持。</em></p>
</div><p><em>Editorial content is independently produced and follows the</em> highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div class="lb-trans"><p><em>编辑内容独立制作，遵循</em> 最高标准 <em>的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>
</div>

uBriGene 与 Cellinfinity BIO 合作以加速体内 CAR-T 疗法的发展